Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics

João Conde, Chenchen Bao, Daxiang Cui, Pedro V. Baptista, Furong Tian

Research output: Contribution to journalArticlepeer-review

82 Citations (Scopus)


Inspired by the ability of SERS nanoantennas to provide an integrated platform to enhance disease targeting in vivo, we developed a highly sensitive probe for in vivo tumour recognition with the capacity to target specific cancer biomarkers such as epidermal growth factor receptors (EGFR) on human cancer cells and xenograft tumour models. Here, we used ~ 90 nm gold nanoparticles capped by a Raman reporter, encapsulated and entrapped by larger polymers and a FDA antibody-drug conjugate - Cetuximab (Erbitux®) - that specifically targets EGFR and turns off a main signalling cascade for cancer cells to proliferate and survive. These drug/SERS gold nanoantennas present a high Raman signal both in cancer cells and in mice bearing xenograft tumours. Moreover, the Raman detection signal is accomplished simultaneously by extensive tumour growth inhibition in mice, making these gold nanoantennas ideal for cancer nanotheranostics, i.e. tumour detection and tumour cell inhibition at the same time.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalJournal of Controlled Release
Issue number1
Publication statusPublished - 10 Jun 2014


  • Antibody-drug conjugates
  • In vivo tumour targeting
  • Nanotheranostics
  • Raman fingerprints
  • SERS


Dive into the research topics of 'Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics'. Together they form a unique fingerprint.

Cite this